A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis — StellaPhase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(3 sites)
China
Department of RheumatologyTongji Hospital, Wuhan, Hubei Tongji Hospital, Wuhan, Hubei Tongji Hospital, Wuhan, Hubei Age range
18 Years – 80 Years
Last updated January 2026